Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-23T09:06:59.686Z Has data issue: false hasContentIssue false
  • English
  • Français

Preclinical Alzheimer's disease

Published online by Cambridge University Press:  20 March 2014

P Gil-Gregorio  and
R Yubero-Pancorbo
P Gil-Gregorio
Affiliation:
Memory Unit, Geriatric Department, Hospital Clinico San Carlos, Madrid, Spain
R Yubero-Pancorbo*
Affiliation:
Memory Unit, Geriatric Department, Hospital Clinico San Carlos, Madrid, Spain
*
Address for correspondence: Raquel Yubero, Hospital Clínico San Carlos, Servicio de Geriatría, c/Profesor Martín Lagos, s/n 28040, Madrid, Spain. Email: raquel_yubero@hotmail.com
Get access Rights & Permissions [Opens in a new window]

Summary

Recently, diagnostic criteria for preclinical Alzheimer's disease have been proposed. These describe and define three stages of disease. Stage I is focused on asymptomatic cerebral amyloidosis. Stage II includes evidence of synaptic dysfunction and/or early degeneration. Finally, stage III of the disease is characterized by the beginning of cognitive decline.

Keywords

Alzheimer’s diseasepreclinical stagesamyloidosisneurodegenerationcognition
Type
Review Article
Information
Reviews in Clinical Gerontology , Volume 24 , Issue 2 , May 2014 , pp. 117 - 121
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Sperling, RA, Aisen, PS, Beckett, LAet al.Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer´s Association workgroups on diagnostic guidelines for Alzheimer's Disease. Alzheimer's Dementia 2011; 7: 280–92.CrossRefGoogle ScholarPubMed
2Jack, CR, Knopman, DS, Jagust, WJet al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119–28.CrossRefGoogle ScholarPubMed
3Shaw, LM, Vanderstichele, H, Knapik-Czajla, Met al.Cerebrospinal fluid biomarkers signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403–13.CrossRefGoogle ScholarPubMed
4Ikonomovic, MD, Klunk, WE, Abrahamson, EEet al.Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630–45.CrossRefGoogle Scholar
5Mintun, M, Saha, K, Fleisher, Aet al.Florbetapir PET imaging of β amyloid plaques is highly correlated with histopathological assays at autopsy. J Nucl Med 2010; 51: abstract 387.Google Scholar
6Hample, H, Buerger, K, Zinkowsky, Ret al.Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004; 61: 95–102.CrossRefGoogle Scholar
7Jagust, WJ, Landau, SM, Shaw, LMet al.Relationship between biomarkers in aging and dementia. Neurology 2009; 73: 1193–99.Google Scholar
8Dickerson, BC, Wolk, DA. MRI cortical thickness biomarkers predict AD-like CSF and cognitive decline in normal adults. Neurology 2012; 78: 84–90.CrossRefGoogle ScholarPubMed
9Becker, JA, Hedden, T, Carmasin, Jet al.Amyloid β associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69: 1032–42.Google Scholar
10Seidenberg, M, Guidotti, I, Nielson, KAet al.Semantic memory activation in individuals at risk for developing Alzheimer's disease. Neurology 2009; 73: 612–20.Google Scholar
11Fernandez, A, Turrerro, A, Zuluaga, P, Gil Gregorio, P, del Pozo, F, Maestu, F, Moratti, S. MEG delta mapping along the healthy aging-Alzheimer's disease continuum: diagnostic implications. JAD 2013; 35: 495–501.Google Scholar
12Dubois, B, Feldman, HH, Jacova, Cet al.Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734–46.CrossRefGoogle ScholarPubMed
13Ewers, M, Insel, PS, Stern, Y, Weiner, MW. Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology 2013; 80: 1194–201.CrossRefGoogle ScholarPubMed
14Knopman, DS, Caselli, RJ. Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. Neurodegener Dis Manag 2012; 2: 183–95.Google Scholar
15Schmid, NS, Taylor, KI, Foldi, NS, Berres, M, Monsch, AU. Neuropsychological signs of Alzheimer's disease 8 years prior to diagnosis. JAD 2013; 34: 537–46.CrossRefGoogle ScholarPubMed
16Yubero, R, Salmon, D. Valoración Cognitiva en el Anciano. In Gil Gregorio, P (ed), Tratado de Neuropsicogeriatría, pp. 81–89. Sociedad Española de Geriatría y Gerontología SEGG. Madrid, Ergón; 2010.Google Scholar
17Mandal, PK, Joshi, J, Saharan, S. Visuospatial perception: an emerging biomarker for Alzheimer's disease. JAD 2013, 31 (suppl 3): S117–35.CrossRefGoogle Scholar